COVID-19, rheumatic diseases and immune dysregulation-a perspective.

The COVID-19 pandemic has resulted in widespread hospitalisations and deaths around the world. As patients with rheumatic diseases generally have increased risk of infections and complications, understandably, there is significant concern of the impact of SARS-CoV-2 on these patients. However, there is a paucity of data in rheumatic patients. We review mechanisms through which SARS-CoV-2 results in infection, including ACE2 receptor, and complications (including immune dysregulation, thrombosis and complement activation). We assess these pathways in patients with rheumatic disease and those on immune modulating therapy. Although data thus far does not appear to show worse outcomes in rheumatic patients as a whole, given alterations in the underlying immune pathways in certain diseases (such as systemic lupus erythematosus), we posit that the risk is not equal in all rheumatic patients. We also discuss the benefit of underlying disease control with respect to COVID-19 risk reduction and potential increased risk of disease flares following viral infection from an immune standpoint.

Introduction

By late October 2020, severe acute respiratory coronavirus 2 (SARS-CoV-2) has infected over 43 million people globally, with over 1.1 million deaths and thousands more hospitalisations for direct complications from COVID-19 [1]. Prevalence of COVID-19 is equal between the genders, although men are at higher risk for severe outcomes and death [2]. This is particularly concerning as there are no proven therapies for this infection as of yet and vaccine developments are still underway. Many immunocompromised patients, particularly in rheumatic diseases, may theoretically develop increased complications from COVID-19, although preliminary studies have been inconclusive [3-6]. Using knowledge of the immunopathogenesis of rheumatic diseases and the expanding knowledge of COVID-19 immune responses, we aim to describe some of the similarities between the immune dysregulation in rheumatic diseases and COVID-19. We also aim to summarise the risk of developing severe COVID-19 in rheumatic disease and to therapies utilised for rheumatic diseases, in addition to how these therapies can be utilised to target the inflammatory complications associated with COVID-19.

COVID-19 viral entry in aging and rheumatic diseases

In many patients with rheumatic diseases (e.g. rheumatoid arthritis and systemic lupus erythematosus), there is a documented higher risk of severe infectious complications compared to the general population, which may relate to the degree of disease activity [7, 8]. There is little data however that patients with rheumatic conditions as a whole may have an increased risk for contracting COVID-19, although evidence is limited. Like other viruses, SARS-CoV-2 requires entry into cells in order to replicate. This, in turn, results in cellular responses aimed at quelling the viral infection. The primary cellular receptors for SARS-CoV-2 which bind the viral spike protein is angiotensin-converting enzyme 2 (ACE2), and its co-receptor, transmembrane serine protease 2 (TMPRSS2) [9, 10]. Patients with co-morbidities for cardiovascular disease including obesity, hypertension and chronic kidney disease have higher levels of circulating ACE2 [11, 12]. These patients have been shown to have more severe COVID-19. These co-morbidities are present more frequently in patients with rheumatic diseases. Interestingly, both ACE2 and TMPRSS2 are transcriptionally expressed at higher levels in respiratory epithelial cells in elderly patients [13]. ACE2 is also hypomethylated and overexpressed in lupus [14]. Apolipoprotein E, a known inducer of ACE2, is present in higher levels in patients with rheumatic and cardiovascular diseases [15, 16], suggesting that ACE2 levels are likely elevated in rheumatic patients. This theoretically increases the risk of contracting COVID-19 in patients with rheumatic diseases. Moreover, cytokines that are elevated in patients with rheumatic diseases (e.g. TNFα) may promote the expression of ACE2 [17], and disease modifying therapies (e.g. hydroxychloroquine), may reduce their expression [18]. This suggests that maintaining adequate control of rheumatic diseases may be important in reducing the risk of infection. This notion is supported by recent data from prospective cohorts showing that the incidence of COVID-19 infections in patients receiving disease modifying therapies (e.g. TNF alpha inhibitors or JAK inhibitors) for inflammatory conditions (e.g. inflammatory arthritis or inflammatory bowel disease) was comparable to that of the general population [4, 19].

Immune dysregulation in COVID-19, aging and rheumatic diseases

In both active rheumatic diseases (such as systemic lupus erythematosus, systemic sclerosis and myositis) and anti-viral immune response, there is generation of a robust type I interferon (IFN) response. IFN responses are important in limiting intracellular viral replication and in the generation of the appropriate immune response required for proper host defense. In many rheumatic diseases, elevated disease activity is associated with increased IFN signals [20]. Based on the role of IFN responses in viral infection, the increased IFN signals in active rheumatic diseases may be theorised to assist with viral clearance during an infection. Intriguingly, aging results in diminished type I interferon responses intracellularly [21]. Recently, inborn errors against type I interferon immunity [22] and autoantibodies against type I interferon [23] have been detected in patients with severe COVID-19 in contrast to patients with mild/asymptomatic disease, suggesting that impaired interferon response plays a key role in disease pathogenesis.

In patients with severe COVID-19, there is a prominent cytokine release syndrome (CRS or cytokine storm). Acute respiratory distress syndrome, which is a consequence of the cytokine storm and clinically presents as respiratory and/or heart failure, is a frequent cause of mortality in patients hospitalised with COVID-19 [24]. Cytokine storm stems from the infected individual’s response to SARS-CoV-2 in the absence of negative counter-balancing signals as was suggested by the presence of CRS in patients infected with SARS-CoV-1 (which is structurally related to SARS-CoV-2) who had minimal viral titres [25, 26]. In COVID-19, CRS results in unbalanced cytokine responses and elevated levels of inflammatory mediators including IL-6, IL1b and TNF-a [27-29]. Elevated IL-6 levels have been associated with poor outcomes in COVID-19, including mechanical ventilation and mortality in hospitalized patients [30].

One of the primary mechanisms for the loss of immune homeostasis, with subsequent CRS, in patients with COVID-19 stems from the increased activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome and reduced anti-viral type I interferon response [31]. This imbalance results in increased levels of IL-1β and IL-18 generated by an activated NLRP3 inflammasome [32]. These cytokines promote the release of other inflammatory signals including IL-6 and TNFα. Downstream, the pro-inflammatory cytokines promote the release of additional inflammatory signals such as those from activated monocytes, and TH17 cells [33]. Natural killer (NK) cells normally counteract these inflammatory signals by killing viral-infected cells, activated monocytes and T cells, thereby acting to reduce the inflammatory response [34, 35]. In COVID-19, however, NK cell number and function are reduced in patients with severe disease, thereby potentiating the CRS [36].

Patients with cardiovascular co-morbidities, such as diabetes, hypertension, obesity and increased age, are at increased risk for COVID-19 complications [37], suggesting that some of the relevant signals important in maintaining immune homeostasis to counterbalance inflammatory cytokine release are less functional in these patients. These co-morbidities are often more prevalent in patients with rheumatic diseases and there may be an increased risk of cytokine storm in rheumatic patients. Aging is associated with the development of chronic inflammation and a general reduction in immune diversity [38]. The aged innate immune response is characterized by increased secretion of pro-inflammatory cytokines (TNF, IL-6 and IL-1β) and a decrease in the number and function of dendritic cells (DCs) and macrophages. This leads to poor priming of T cells and diminished clearance of infectious agents and apoptotic cells through phagocytosis [39, 40]. Cell-mediated immunity suffers a loss of naïve lymphocytes in the aged population, with an increased expansion of antigen-specific memory lymphocytes, leading to an inadequate immune response to newly encountered antigens and an increased susceptibility to infection [39-41]. NK cells as mediators of immune regulation play a pivotal role in this immune senescence. NK cell production and proliferation are reduced in aging, though the absolute number of NK cells is higher, likely due to the accumulation of long-lived NK cells [42]. The expression of natural cytotoxicity receptor (NCR) NKp30 is also reduced in aging. This not only decreases granule-mediated cytotoxicity but also negatively impacts the adaptive immune response through obstructed NK-DC crosstalk [43]. Neutrophil apoptosis by NK cells is mediated through death receptor ligation by NCR NKp46. Finally, both NKp30+ and NKp46+ NK cell expression is reduced in older individuals [44] which further impairs the elimination of virally infected cells and infected monocytes releasing inflammatory cytokines.

Similarly, in many patients with rheumatic diseases (e.g. systemic lupus erythematosus, Sjogren’s syndrome, systemic sclerosis and systemic juvenile idiopathic arthritis), there is a disparity in negative signals that counterbalance CRS. For example, systemic lupus erythematosus (SLE) patients have a numerical deficit and reduced cytotoxicity of their NK cells. In addition, SLE patients may foster autoantibodies to both HLA class I–binding receptors (NKG2A, NKG2C) and multiple killer cell immunoglobulin-like receptors, which results in the dysregulation of self/non-self-recognition [45, 46]. Although numerical deficits are less frequent in patients with Sjogren’s syndrome and systemic sclerosis (SSc), both groups of patients have reduced NK cell cytotoxicity [47]. Likewise, in patients with chronic lung diseases secondary to rheumatic diseases, NK cell functions are also diminished. Patients with juvenile idiopathic arthritis (JIA) and rheumatoid arthritis–related macrophage activation syndrome also harbour diminished NK cell cytolytic activities [48]. Figure 1 illustrates the similarities in the reduction of NK cell function between SARS-CoV-2 infection and SLE, ultimately leading to hyper-inflammation and organ dysfunction from cytokine release. Hence, patients with rheumatic diseases (especially SLE) may be at increased risk for COVID-19, particularly if their diseases are not adequately controlled.

Fig. 1

a SARS-CoV-2 directly suppressed NK cell function through binding of ACE2 receptors on the cell surface. This reduces NK cell ability to kill both viral-infected cells and activated immune cells, increasing the production of pro-inflammatory cytokines and contributing to the development of hyper-inflammation. b Similarly, in rheumatic diseases, dysfunctional NK cells are not effective at clearing the immune cells which are activated by the binding of an unknown antigen (via an antigen presenting cell) to a naive T cell. Downstream, this leads to production of pro-inflammatory cytokines, which ultimately lead to organ damage

COVID-19 associated thrombosis, complement activation and relevance to rheumatic diseases

It is well-established that coagulation is intricately linked with inflammation, particularly as elevated IL-6 levels and C-reactive protein (CRP) may be associated in promoting the formation of thrombosis. Postmortem analysis of patients with COVID-19 have shown evidence of thrombotic microangiopathy and neo-angiogenesis from both renal and lung samples, without evidence for vasculitis [49, 50]. Lupus anticoagulants are elevated in 50% of patients with severe COVID-19 and in 91% of patients with severe disease and a prolonged activated partial thromboplastin time (aPTT) [51, 52]. Although these antibodies are associated with thrombosis normally, the presence of these antibodies does not appear to correlate with the risk of thrombosis in COVID-19, as significant antiphospholipid antibodies were not present in patients with COVID-19 and venous thromboembolism [53]. Bikdeli et al. recently highlighted the development of thromboembolic disease as a severe manifestation of SARS-CoV-2 infection [54]. Thrombotic complications were found to be present in more than 30% of cases in COVID-19 patients admitted to intensive care. Similarly, elevated mannose–binding lectin (MBL), which is known to activate the lectin pathway in the complement system, promotes thrombosis. Localised activation of other complement pathways such as the classical or lectin pathways may also result in increased risk of thrombosis in areas of tissue damage, such as the lungs [55].

Like patients with COVID-19, patients with uncontrolled rheumatic diseases have increased risk for thrombosis. This is most notable in patients with SLE [56], although it has also been described in patients with ANCA vasculitis [57] and Sjogren’s syndrome [58]. The thrombotic risks appear to improve once the diseases are more quiescent, although persistent and increased hypercoagulability has been demonstrated in patients during disease remission [59] and may be associated with activation of the alternative pathway and NETosis [60]. Similarly, thrombosis stemming from circulating lupus anticoagulants may be exacerbated by inflammatory insults, such as acute infections. Although this has not been directly shown in patients with SLE and COVID-19, patients with SLE and COVID-19 appear to have more severe courses of hospitalization compared to other patients with rheumatic conditions [61].

COVID-19-associated immune dysregulation

With the unbalanced immune response in COVID-19 patients with vascular co-morbidities, it is conceivable to suspect that patients with rheumatic diseases may be at increased risk for immune dysregulation–related complications as they are more likely to have increased vascular co-morbidities. COVID-19 infection may also lead to underlying flare of rheumatic disease. This is most likely in disease subsets of inflammatory arthritis [62] and ANCA-associated vasculitis [63], where exposure to viral infections has been shown to predispose these patients to disease flares [62]. It is also seen in different forms of reactive arthritis that may be self-limited (e.g. parvovirus B19, hepatitis B, rubella) or longer lasting (e.g. chikungunya and hepatitis C). In contrast to these other viruses, coronaviruses are usually associated with arthralgia, but not frank arthritis [64]. It is unknown, however, if SARS-CoV-2-related arthralgia is self-limited or if it may result in a more chronic inflammatory arthritis. Indeed, exposure to viruses, such as coronavirus and parainfluenza, may increase the likelihood for developing rheumatoid arthritis [65]. Thus far, there have been three reports of patients presenting with a reactive arthritis–like pattern following SARS-Co-V-2 infection [66-68]. Like arthralgia, myalgias are also common in patients with COVID-19 [66] and rarely, myositis can ensue in patients with COVID-19 [69]. As the anti-viral response in patients without a CRS may promote pathways associated with a disease relapse, it would not be farfetched to suspect that certain patients, particularly those with a connective tissue disease (e.g. SLE, Sjogren’s syndrome, inflammatory myositis), may develop a disease flare. However, this has not yet been thoroughly described in patients in relation to SARS-CoV-2 infection.

Lung complications, such as interstitial lung disease, are common in patients with rheumatic illness, particularly in connective tissue diseases [70]. This is clinically challenging, particularly as patients infected with SARS-CoV-2 may also develop lower respiratory infections and pulmonary thrombosis. In a case series of 17 patients with SLE diagnosed with COVID-19 by Mathian et. al., a majority of them (76%) developed respiratory complications [71]. Similarly, in a cohort of patients with rheumatic diseases, a disproportionately larger number of patients with required mechanical ventilation and a prolonged hospitalisation, compared to patients with other rheumatic diseases [3]. It is difficult to determine if the respiratory complications in these SLE patients developed in these studies stemmed primarily from the SARS-CoV-2 infection, SLE flare or a combination of COVID-19 potentiating a respiratory SLE flare. Unfortunately, many of the clinically available biomarkers that are reported to be associated with COVID-19 are also abnormal in rheumatic diseases (e.g. NK cell dysfunction, elevated IL-6, CRP, hypocomplementemia), and they do not always parallel the disease activity in these patients [72-74]. Hence, biomarkers that can distinguish rheumatic disease flares from COVID-19 are desperately needed.

The potential risk of disease flare or complications of COVID-19 with active rheumatic disease supports the notion that patients with rheumatic conditions should be monitored more closely during the pandemic.

Infectious risks associated with therapies in rheumatic diseases

Corticosteroids are commonly used in patients with rheumatic diseases; however, they may increase the risk of contracting COVID-19. Corticosteroids, particularly at increased doses, reduce innate, cell-mediated and humoral immune responses to infection and increase the risk of opportunistic infections [75]. In patients with other severe coronavirus infections, such as SARS and MERS, some studies suggested that high doses of corticosteroids resulted in increased mortality [76]. In a large retrospective cohort of patients with inflammatory bowel disease (IBD), the use of high-dose corticosteroids (prednisone > 20 mg/day) was associated with severe COVID-19 and increased mortality [77]. Prednisone > 10 mg/day was associated with increased COVID-19 severity in patients with rheumatic illnesses [5]. It is unclear if the increased risk is conferred from corticosteroid use or from the dysregulated immunity stemming from rheumatic disease activity. Regardless, corticosteroids increase risk of secondary infections. Many patients with COVID-19 are at risk of developing co-infections, which in turn increases their risk of developing complications including increased hospitalization periods and/or mortality [78]. However, it has been recently postulated that acute corticosteroid use in patients with a CRS related to COVID-19 may be beneficial [79]. It is important, therefore, to weigh the potential benefits (e.g. treating the severe CRS associated with COVID-19 and/or the inflammatory component of rheumatic diseases in the acute setting with the risk of infections) with the risk of long-term corticosteroids.

Many therapies utilised in the treatment of rheumatic diseases were initially thought to be associated with an increased risk of complications from COVID-19, but they are now being investigated as potential therapeutic strategies in the treatment of COVID-19-related cytokine storms. For example, mice deficient in TNFα or its receptor were protected from a severe form of a SARS-CoV infection [80]. This is not surprising and is likely applicable to SARS-CoV-2 as TNFα levels are elevated in patients with COVID-19 [27, 28], and elevated levels of TNFα promotes the expression of ACE2, which increases viral entry into cells [81]. Therapies targeting this pathway have been suggested to potentially treat patients with severe COVID-19 [82]. Therefore, it is no surprise that patients with rheumatic diseases (e.g. rheumatoid arthritis and psoriatic arthritis), and related immune-mediated inflammatory conditions (e.g. IBD) which utilise higher doses of agents targeting this pathway do not appear to have an increased risk of COVID-19 [83]. Similar findings have been observed in COVID-19 patients with agents targeting other pathways used in rheumatic diseases (e.g. anti-IL-17 and anti-IL-12/23 therapies). Indeed, therapies used for treating rheumatic conditions that target cytokine pathways elevated in severe COVID-19 (e.g. IL-6 and IL-1β) have been shown to be beneficial in small single-arm studies [83, 84]. Larger comparative studies assessing the efficacy of these agents are currently underway [85]. Table 1 summarises available information on COVID19 outcomes in patients with rheumatic diseases on immunomodulatory therapies.

Table 1

Summary of select published studies assessing SARS-CoV-2 infection in patients with rheumatic diseases

Reference	Jurisdiction	Study type	Patient population	Outcomes
Avouac, et al 2020 [86]	France/Italy	Case series	3 patients with SSc on rituximab (including 1 with ILD)	Deaths: 0 Mechanical ventilation: 0 At reporting, 1 patient discharged, 2 on general ward All patients had complete B cell depletion
Favalli, Monti, et al, 2020 [87]	Italy	Retrospective cohort (survey)	Baseline: 955 patients on bDMARD or tsDMARD 6 confirmed cases (3 RA, 2 SpA, 1 sarcoidosis; 5 TNF-i, 1 abatacept) 144 suspected cases	Confirmed cases: 3 Hospitalisations (supplemental oxygen): Deaths: 0 Mechanical ventilation: 0 Suspected cases: Deaths: 0 Mechanical ventilation: 0
Favalli, Agape, et al, 2020 [56]	Italy	Retrospective cohort (survey)	Baseline: 123 patients with CTD. 60% of patients on csDMARDs. Mean steroid dose 5.3 mg daily. bDMARDs: 18 belimumab, 5 rituximab, 2 IL-6 1 confirmed case (SSc with ILD on rituximab + HCQ) 14 suspected cases	Confirmed case: Death: 1 Suspected cases: Deaths: 0 Mechanical ventilations: 0
Fredi et al, 2020 [88]	Italy	Retrospective cohort + case-control study (hospitalised COVID-19 with/without COVID-19)	Baseline: 1525 rheumatic patients at single centre 65 confirmed cases: 43 on glucocorticoid (average 35 mg weekly). 27 bDMARDs (including 4 rituximab) 52 suspected cases	Confirmed cases: 72% Hospitalisations. 15% deaths (CV co-morbidities in majority) Deaths: 4% Suspected cases: 0 Case control: No difference in hospitalised patients with COVID19 with and without rheumatic diseases
Gianfrancesco et al, 2020 [5]	Global	Retrospective cohort	600 patients from COVID19 Global Rheumatology Alliance physician-reported registry including: rheumatic diseases: 230 RA, 85 SLE, 74 PsA, 48 SpA, 44 vasculitis Medications: 231 on bDMARDs or tsDMARDs; 11 on prednisone > 10 mg/day	Hospitalisations: 46% Deaths: 9% Hospitalisations: -No difference with rheumatic diseases -Increased with co-morbidities (HTN, lung disease, DM, CVD, CKD) -Increased OR with prednisone > 10 mg/day (OR 2.05) -Reduced with TNF-i (OR 0.40) Patients on TNF-I had reduced odds of hospitalisation (OR 0.40) Patients on prednisone > 10 mg/day had increased odds of hospitalisation (OR 2.05) No differences with other medications
Gisondi et al, 2020 [89]	Italy	Retrospective cohort	Baseline: 5206 patients with PsO on bDMARDs 6 confirmed cases	Hospitalisations: 4 Mechanical ventilation: 1 Death: 0 -3 had co-morbidities (HTN, DM, CKD, obesity)
Haberman et al 2020 [18]	USA	Case series	86 patients with immune-mediated inflammatory diseases on therapy	Hospitalisations: 14 ICU: 7 Death: 1 50% hospitalised on bDMARDs/tsDMARDs. 76% ambulatory on bDMARDs/tsDMARDs Hospitalised patients more likely to have co-morbidities (HTN, DM, and obstructive lung disease)
Moiseev et al, 2020 [90]	Russian Federation	Retrospective cohort	Baseline: 902 patients in ICU with COVID19 10 had rheumatic disease (5 RA, 1 PsA, 1 SpA, 1 SLE, 2SSc) Baseline medications not reported	Deaths: 5 (all had co-morbidities; 2 RA, 1 SpA, 2 SSc) ICU: 3 (all had co-morbidities; 2 RA, 1 SLE) Recoveries: 2 (both had HTN; 1 RA, 1 PsA)
Monti et al, 2020 [91]	Italy	Retrospective cohort	Baseline: 320 RA/PsA patients on bDMARDs/tsDMARDs 4 confirmed cases 4 suspected cases	Confirmed cases: 1 hospitalisation (supplemental oxygen) Suspected cases: Hospitalisations: 0 Deaths:4
Sanchez-Piedra et al, 2020 [92]	Spain	Cohort	Baseline: 6600 rheumatic disease patients on bDMARDs/tsDMARDs in BIOBADASER database41 COVID-19 cases at 15 hospitals in the registry 31 confirmed cases 10 suspected cases	Deaths: 3 ICU: 6 Hospitalisations: 28 Deaths in: 63M RA on anakinra + pred 5 mg/day (smoker, BMI 34.6); 56F SpA on secukinumab (past smoker, BMI 28.4); 91F vasculitis on rituximab + pred 5 mg/day
Tomelleri et al, 2020 [93]	Italy	Retrospective cohort	Baseline: 162 LVV patients (95 GCA; 67 TA)—medications: steroid, MTX, TNF-i, IL-6, JAKi 4 confirmed cases	Hospitalisations: 2 Deaths: 0 -79M GCA/HTN on prednisone 17.5 mg; 79M GCA/CVD/CKD on pred 7.5 mg
Wallace et al, 2020 [94]	USA	Cohort	5 SLE (80% on HCQ) vs. 31 rheumatic patients with COVID-19	SLE: 80% hospitalised; 60% mechanical ventilation; 20% death Overall cohort: 64% Hospitalised: 19% Mechanical ventilation: 13% Death: 0

Finally, several groups have suggested that agents targeting anti-CD20, which depletes a large proportion of circulating B cells, may pose an increased risk in patients with COVID-19 [95]. These conclusions are based on the idea that humoral immunity provided by B cells may be important in reducing the viral titres targeting SARS-CoV-2, and potentially promoting the elimination of infected cells via cell-mediated immunity and antibody dependent cellular toxicity (ADCC) [96]. However, there does not appear to be an increased risk of severe COVID-19 in patients with X-linked agammaglobulinemia, or patients treated with anti-CD20 agents who have rheumatic or other inflammatory conditions (e.g. multiple sclerosis) [97-99]. In contrast, patients with combined forms of common variable immune deficiency with both impaired cell-mediated and impaired humoral immunity may be more affected. Arguably, cell-mediated immunity may be more important in reducing the risk of severe CRS and COVID-19. Interestingly, a report of a COVID-19 in a patient with ANCA-associated vasculitis treated with rituximab showed mild symptoms [100]. It is clear, however, that patients treated with these agents have an increased risk of developing other infections (e.g. encapsulated bacteria). Hence, careful monitoring of total immunoglobulin levels (IgG) to ensure that they are in the therapeutic range (7–10 g/L) are important to minimise these risks.

Conclusion and future perspective

Like many other viruses, SARS-CoV-2 poses its own unique challenges, particularly in patients with rheumatic diseases as they also carry a predisposition for immune dysregulation. Careful interpretation is required when assessing disease biomarkers, many of which may indicate either a rheumatic flare or an elevation in COVID-19 disease severity. Most studies suggest that patients with rheumatic disease are not at increased risk for acquiring COVID-19, but that their COVID-19 symptoms may be more severe. However, there is granularity in assessing this issue, as patients with systemic lupus erythematosus may be at increased risk of severe COVID-19. Importantly, there is accumulating evidence that COVID-19 may result in flares of rheumatic disease. Therefore, focus in the case of rheumatic diseases should thus be on making sure that the patient’s underlying disease is well managed and that their symptoms and immune dysfunction are being well regulated, as this may help protect them from an aggravated onslaught of immune dysregulation brought on by COVID-19.